1. Pink Sheet
  2. >>Product Reviews
  3. >>Approvals

Row Erupts Over “Third Way” For Biosimilar Approvals In Colombia

 
• By Francesca Bruce

Colombia’s health ministry has accused the R&D-based pharmaceutical industry association of prioritizing monopolies over patients after its attempts to suspend legislation that promises a faster route to market for biosimilars.

Medicine
A row erupts in Colombia over approval pathways for biosimilars • Source: Shutterstock

Colombia’s health ministry and the international R&D-based pharmaceutical industry association, Afidro, are at loggerheads over legislation that gives biosimilars a faster route to market. Afidro has requested that a decree be suspended, claiming that it will lead to the approval of medicines that have not been properly tested. Meanwhile, the health ministry has accused the association of creating overly onerous barriers to competition.

The legislation in question is Decree 1782 of 2014, which seeks to establish the procedures and requirements for evaluating and...

More from Approvals

US FDA’s June Approval Forecast: Infection Prevention, Cancer And HAE

 
• By Bridget Silverman

Upcoming FDA user fee goal dates include novel products from a busy lung cancer pipeline, a single-dose passive immunization against RSV for infants, what could be the first oral HAE acute treatment, and a first-in-class HAE preventive antibody.

New EU Approvals

 
• By Neena Brizmohun

The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include two new products, one of which is Vyjuvek, Krystal Biotech's advanced therapy for treating dystrophic epidermolysis bullosa.

Autolus’s Aucatzyl And GSK’s Blenrep Among 10 New Drugs To Get EMA Nod

 
• By Vibha Sharma

The European Medicines Agency has OKd 10 new medicines for EU-wide approval, including a CAR-T therapy for treating acute lymphoblastic leukemia. Two drugs were, however, rejected.

EU Authorization Before US? Biologics Manufacturing Is Likely To Blame

 
• By Bridget Silverman

In the infrequent cases when EU authorization precedes US FDA approvals of new products, biologics manufacturing issues are usually to blame, a Pink Sheet analysis found.

More from Product Reviews

EMA Touts Faster Global Post-Approval Changes Via Regulatory Reliance

 
• By Eliza Slawther

The European Medicines Agency says that a regulatory reliance pilot that it is supporting to speed up assessments of post-approval changes appears to be accelerating evaluation timelines in non-EU countries.

New EU Approvals

 
• By Neena Brizmohun

The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include two new products, one of which is Vyjuvek, Krystal Biotech's advanced therapy for treating dystrophic epidermolysis bullosa.

US FDA Meeting Drought Ends … With A Vengeance

 
• By Michael McCaughan

The first 100 days of the Trump Administration were notable for an extraordinary decline in the number of public meetings hosted by the US Food and Drug Administration. But the schedule changed quickly.